Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease —Author's reply
This article is linked to Colizzo and Friedman, and Selinger et al papers. To view these articles visit https://doi.org/10.1111/apt.14399 and https://doi.org/10.1111/apt.14334. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: C. P. Selinger, G. C. Parkes, T. Raine Tags: INVITED EDITORIALS Source Type: research

Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease
This article is linked to Selinger et al papers. To view these articles visit https://doi.org/10.1111/apt.14334 and https://doi.org/10.1111/apt.14403. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: F. P. Colizzo, L. S. Friedman Tags: INVITED EDITORIALS Source Type: research

Editorial: anti ‐TNF therapy and myopenia in Crohn's disease—another step towards personalised medicine. Authors’ reply
This article is linked to Ding et al and Murray papers. To view these articles visit https://doi.org/10.1111/apt.14293 and https://doi.org/10.1111/apt.14392. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: N. S. Ding, G. Malietzis, A. L. Hart Tags: INVITED EDITORIALS Source Type: research

Editorial: anti ‐TNF therapy and myopenia in Crohn's disease—another step towards personalised medicine
This article linked to Ding et al papers. To view these articles visit https://doi.org/10.1111/apt.14293 and https://doi.org/10.1111/apt.14409. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: C. D. Murray Tags: INVITED EDITORIALS Source Type: research

Editorial: alfapump —an alternative to large‐volume paracentesis for patients with refractory ascites? Authors’ reply
This article is linked to Stirnimann et al and Macdonald and Jalan papers. To view these articles visit https://doi.org/10.1111/apt.14331 and https://doi.org/10.1111/apt.14390. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: G. Stirnimann, A. De Gottardi Tags: INVITED EDITORIALS Source Type: research

Editorial: alfapump —an alternative to large‐volume paracentesis for patients with refractory ascites?
This article is linked to Stirnimann et al and Stirnimann and De Gottardi papers. To view these articles visit https://doi.org/10.1111/apt.14331 and https://doi.org/10.1111/apt.14415. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: S. Macdonald, R. Jalan Tags: INVITED EDITORIALS Source Type: research

Editorial: patient assessment of constipation ‐symptoms (PAC‐SYM) questionnaire has a minimal important difference
This article is linked to Yiannakou et al paper. To view this article visit https://doi.org/10.1111/apt.14349. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: Y. A. Saito, M. Camilleri Tags: INVITED EDITORIALS Source Type: research

Editorial: Non ‐breaking news! High‐dose PPIs likely do not cause fractures
This article is linked to Kumar et al. To view this article visit https://doi.org/10.1111/apt.14345. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: L. E. Targownik Tags: INVITED EDITORIALS Source Type: research

Editorial: long ‐term effectiveness of elimination diet therapy for eosinophilic oesophagitis—is the glass half full or half empty?
This article is linked to Reed et al paper. To view this article visit https://doi.org/10.1111/apt.14290. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: N. Gonsalves, I. Hirano Tags: INVITED EDITORIALS Source Type: research

Editorial: a step forward in refining prognostication for patients with HIV ‐associated hepatocellular carcinoma—Authors’ reply
This article is linked to Pinato et al and Giannini papers. To view this article visit https://doi.org/10.1111/apt.14356 and https://doi.org/10.1111/apt.14374. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: D. J. Pinato, N. Br äu, M. Bower Tags: INVITED EDITORIALS Source Type: research

Editorial: a step forward in refining prognostication for patients with HIV ‐associated hepatocellular carcinoma
This article is linked to Pinato et al papers. To view these articles visit https://doi.org/10.1111/apt.14356 and https://doi.org/10.1111/apt.14394. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: E. G. Giannini Tags: INVITED EDITORIALS Source Type: research

Editorial: recurrence of Helicobacter pylori infection —still the same after all these years… Authors’ reply
This article is linked to Hu et al and Shah and Chey papers. To view these articles visit https://doi.org/10.1111/apt.14319 and https://doi.org/10.1111/apt.14372. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: Y. Hu, J. ‐H. Wan, X.‐Y. Li, Y. Zhu, D. Y. Graham, N.‐H. Lu Tags: INVITED EDITORIALS Source Type: research

Editorial: recurrence of Helicobacter pylori infection —still the same after all these years…
This article is linked to Hu et al papers. To view these articles visit https://doi.org/10.1111/apt.14319 and https://doi.org/10.1111/apt.14386. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: E. Shah, W. D. Chey Tags: INVITED EDITORIALS Source Type: research

Editorial: thiopurine ‐induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype—the perils of ageing. Authors’ reply
This article is linked to Broekman et al and Willington and Gearry papers. To view these articles visit https://doi.org/10.1111/apt.14323 and https://doi.org/10.1111/apt.14370. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: M. M. T. J. Broekman, G. J. Wanten, D. J. Jong Tags: INVITED EDITORIALS Source Type: research

Editorial: thiopurine ‐induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype—the perils of ageing
This article is linked to Broekman et al papers. To view these articles visit https://doi.org/10.1111/apt.14323 and https://doi.org/10.1111/apt.14395. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: A. J. Willington, R. B. Gearry Tags: INVITED EDITORIALS Source Type: research

Editors ’ declarations of Interest
(Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Tags: EDITORIALS Source Type: research

Alimentary Pharmacology and Therapeutics in 2018 ‐ big changes but much the same
(Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Tags: EDITORIALS Source Type: research

Issue Information
(Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Tags: ISSUE INFORMATION Source Type: research

The long ‐term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection
ConclusionOur study highlights that FMT is a durable, safe and acceptable treatment option for patients with recurrent C. difficile infection also in long term, and it shows potential benefits over antimicrobial treatment. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 11, 2017 Category: Drugs & Pharmacology Authors: J. Jalanka, A. Hillamaa, R. Satokari, E. Mattila, V. ‐J. Anttila, P. Arkkila Tags: ORIGINAL ARTICLE Source Type: research

Regional gastrointestinal contractility parameters using the wireless motility capsule: inter ‐observer reproducibility and influence of age, gender and study country
Summary BackgroundThe wireless motility capsule concurrently measures temperature, pH and pressure as it traverses the gastrointestinal tract. AimsTo describe normative values for motility/contractility parameters across age, gender and testing centres. MethodsHealthy participants underwent a standardised wireless motility capsule assessment following an overnight fast and consumption of a meal of known nutritional content. Traces were divided into regions of interest and analysed using 2 software packages (MotiliGI and GIMS Data Viewer). Inter‐observer agreement was independently assessed by 2 investigators. ResultsNorm...
Source: Alimentary Pharmacology and Therapeutics - December 6, 2017 Category: Drugs & Pharmacology Authors: A. D. Farmer, A. ‐M. L. Wegeberg, B. Brock, A. R. Hobson, S. D. Mohammed, S. M. Scott, C. E. Bruckner‐Holt, J. R. Semler, W. L. Hasler, P. M. Hellström, A. M. Drewes, C. Brock Tags: ORIGINAL ARTICLE Source Type: research

Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis
Summary BackgroundEndoscopic and histologic healing are emerging as new therapeutic goals in ulcerative colitis (UC), as these endpoints are associated with less relapse, hospitalization and colectomy. AimTo investigate the association of serum infliximab trough concentrations during maintenance therapy with endoscopic or histologic healing in UC. MethodsIn this multi‐center retrospective cohort study, we included consecutive patients with moderate‐to‐severe UC on infliximab maintenance therapy who had an endoscopic evaluation and underwent therapeutic drug monitoring within three months of the colonoscopy, between F...
Source: Alimentary Pharmacology and Therapeutics - December 6, 2017 Category: Drugs & Pharmacology Authors: K. Papamichael, S. Rakowsky, C. Rivera, A. S. Cheifetz, M. T. Osterman Tags: ORIGINAL ARTICLE Source Type: research

Sofosbuvir and daclatasvir therapy in patients with hepatitis C ‐related advanced decompensated liver disease (MELD ≥ 15)
Summary BackgroundAntiviral therapy for hepatitis C has the potential to improve liver function in patients with decompensated cirrhosis. AimsTo examine the virological response and effect of viral clearance in patients with decompensated hepatitis C cirrhosis all with MELD scores ≥15 following sofosbuvir/daclatasvir ± ribavirin. MethodsWe prospectively collected data on patients who commenced sofosbuvir/daclatasvir for 24‐weeks under the Australian patient supply program (TOSCAR) and analysed outcomes including sustained viral response at 12 weeks (SVR12), death and transplant. Results108 patients (M/F, 79/29;...
Source: Alimentary Pharmacology and Therapeutics - December 5, 2017 Category: Drugs & Pharmacology Authors: G. W. McCaughan, P. A. Thwaites, S. K. Roberts, S. I. Strasser, J. Mitchell, B. Morales, S. Mason, P. Gow, A. Wigg, C. Tallis, G. Jeffrey, J. George, A. J. Thompson, F. C. Parker, P. W. Angus, Tags: ORIGINAL ARTICLE Source Type: research

Systematic review: human gut dysbiosis induced by non ‐antibiotic prescription medications
ConclusionsNon‐antibiotic prescription drugs have a notable impact on the overall architecture of the intestinal microbiome. Further explorations should seek to define biomarkers of dysbiosis induced by specific drugs, and potentially tailor live biotherapeutics to counter this drug‐induced dysbiosis. Many other frequently prescribed drugs should also be investigated to better understand the link between these drugs, the microbiome and health status. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 5, 2017 Category: Drugs & Pharmacology Authors: Q. Le Bastard, G. A. Al ‐Ghalith, M. Grégoire, G. Chapelet, F. Javaudin, E. Dailly, E. Batard, D. Knights, E. Montassier Tags: SYSTEMATIC REVIEW Source Type: research

Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12 ‐month multicentre observational prospective cohort study
ConclusionsWe found no differences in drug levels and disease activity between infliximab innovator and biosimilar in our IBD cohort, indicating that biosimilars are safe and effective. The high proportions of discontinuers were mostly due to elective withdrawal or subjective disease worsening. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 5, 2017 Category: Drugs & Pharmacology Authors: E. M. H. Schmitz, P. J. Boekema, J. W. A. Straathof, D. C. Renswouw, L. Brunsveld, V. Scharnhorst, M. E. C. Poll, M. A. C. Broeren, L. J. J. Derijks Tags: ORIGINAL ARTICLE Source Type: research

Systematic review with network meta ‐analysis: first‐ and second‐line pharmacotherapy for moderate‐severe ulcerative colitis
ConclusionsInfliximab and vedolizumab are ranked highest as first‐line agents, and tofacitinib is ranked highest as second‐line agent, for induction of remission and mucosal healing in patients with moderate‐severe UC, based on indirect comparisons. Head‐to‐head trials are warranted to inform clinical decision‐making with greater confidence. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 4, 2017 Category: Drugs & Pharmacology Authors: S. Singh, M. Fumery, W. J. Sandborn, M. H. Murad Tags: SYSTEMATIC REVIEW WITH META ‐ANALYSIS Source Type: research

Systematic review and network meta ‐analysis: first‐ and second‐line pharmacotherapy for moderate‐severe ulcerative colitis
ConclusionInfliximab and vedolizumab are ranked highest as first‐line agents, and tofacitinib is ranked highest as second‐line agent, for induction of remission and mucosal healing in patients with moderate‐severe UC, based on indirect comparisons. Head‐to‐head trials are warranted to inform clinical decision‐making with greater confidence. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 4, 2017 Category: Drugs & Pharmacology Authors: S. Singh, M. Fumery, W. J. Sandborn, M. H. Murad Tags: SYSTEMATIC REVIEW WITH META ‐ANALYSIS Source Type: research

Interferon ‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis
ConclusionsIFN‐free direct‐acting antiviral therapy of chronic hepatitis C does not alter the short‐term risk for HCC in patients with liver cirrhosis. A reduced HCC incidence may become evident after more than 1.5 years of follow‐up. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 4, 2017 Category: Drugs & Pharmacology Authors: F. Mettke, B. Schlevogt, K. Deterding, A. Wranke, A. Smith, K. Port, M.  P. Manns, A. Vogel, M. Cornberg, H. Wedemeyer Tags: ORIGINAL ARTICLE Source Type: research

Systematic review with meta ‐analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease
ConclusionsThis meta‐analysis revealed an antineoplastic effect of thiopurines on colorectal neoplasia in patients with IBD, particularly amongst patients with UC. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 4, 2017 Category: Drugs & Pharmacology Authors: M. J. Lu, X. Y. Qiu, X. Q. Mao, X. T. Li, H. J. Zhang Tags: SYSTEMATIC REVIEW WITH META ‐ANALYSIS Source Type: research

Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross ‐sectional study using transient elastography
ConclusionsThe number of new cases of cirrhosis diagnosed clearly demonstrates that existing estimates of prevalence are likely to be gross underestimates. Obesity was an important risk factor for cirrhosis within both alcohol users and diabetics. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 1, 2017 Category: Drugs & Pharmacology Authors: D. J. Harman, S. D. Ryder, M. W. James, E. A. Wilkes, T. R. Card, G. P. Aithal, I. N. Guha Tags: ORIGINAL ARTICLE Source Type: research

Systematic review: ileoanal pouch microbiota in health and disease
ConclusionThe microbiota plays an important role in both the inflamed and the healthy ileoanal pouch. A direct causal relationship between individual microbiota changes and inflammation has not yet been established, but manipulation of the ileoanal pouch microbiota may be a novel therapeutic avenue to explore. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 1, 2017 Category: Drugs & Pharmacology Authors: J. P. Segal, S. Oke, G. L. Hold, S. K. Clark, O. D. Faiz, A. L. Hart Tags: SYSTEMATIC REVIEW Source Type: research

Systematic review with network meta ‐analysis: comparative assessment of tofacitinib and biological therapies for moderate‐to‐severe ulcerative colitis
ConclusionsTofacitinib and biologics are efficacious and safe for UC. Further high‐quality research is warranted to establish the best therapeutic option. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - December 1, 2017 Category: Drugs & Pharmacology Authors: S. Bonovas, T. Lytras, G. Nikolopoulos, L. Peyrin ‐Biroulet, S. Danese Tags: SYSTEMATIC REVIEW WITH META ‐ANALYSIS Source Type: research

Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real ‐world results from 18 378 patients in Egypt
ConclusionsReal‐world experience of generic SOF‐DCV in patients with chronic HCV‐G4 proved to be safe and associated with a high SVR12 rate, in patients with different stages of fibrosis. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - November 29, 2017 Category: Drugs & Pharmacology Authors: H. Omar, W. El Akel, T. Elbaz, M. El Kassas, K. Elsaeed, H. El Shazly, M. Said, M. Yousif, A. A. Gomaa, A. Nasr, M. AbdAllah, M. Korany, S. A. Ismail, M. K. Shaker, W. Doss, G. Esmat, I. Waked, Y. El Shazly Tags: ORIGINAL ARTICLE Source Type: research

Review article: gastro ‐oesophageal reflux disease in asthma and chronic obstructive pulmonary disease
ConclusionsDespite the high prevalence of GERD in asthma and COPD, a causal link is lacking. The results of anti‐reflux therapy on pulmonary outcome are inconsistent and contradictory. Future studies will need to identify subgroups of asthmatics and COPD patients that may benefit from anti‐reflux therapy (nocturnal or silent reflux). (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - November 29, 2017 Category: Drugs & Pharmacology Authors: C. Broers, J. Tack, A. Pauwels Tags: REVIEW ARTICLE Source Type: research

Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication ‐ a prospective study for up to 10 years
Summary BackgroundAtrophic gastritis and intestinal metaplasia are premalignant conditions for gastric cancer. Their reversibility by Helicobacter pylori eradication remains controversial. AimTo evaluate the reversibility of atrophic gastritis and intestinal metaplasia by H. pylori eradication with long‐term follow‐up. Methods598 subjects were prospectively enrolled and followed for up to 10 years. They were categorised as H. pylori‐negative (n = 65), H. pylori non‐eradicated (n = 91), and H. pylori‐eradicated (n = 442). Histological assessment was performed for antrum and corpus by Sydney classification. Results...
Source: Alimentary Pharmacology and Therapeutics - November 29, 2017 Category: Drugs & Pharmacology Authors: Y. ‐J. Hwang, N. Kim, H. S. Lee, J. B. Lee, Y. J. Choi, H. Yoon, C. M. Shin, Y. S. Park, D. H. Lee Tags: ORIGINAL ARTICLE Source Type: research

Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES
ConclusionsHBV‐r is relatively uncommon after DAA therapy and not higher than among those treated with a PEG/RBV regimen. The small numbers of persons treated with a DAA regimen who do develop HBV‐r have a shortened survival compared to those without HBV‐r. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - November 28, 2017 Category: Drugs & Pharmacology Authors: A. A. Butt, P. Yan, O. S. Shaikh, A. ‐B. Abou‐Samra Tags: ORIGINAL ARTICLE Source Type: research

Sofosbuvir and velpatasvir with or without voxilaprevir in direct ‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3
ConclusionsThe pan‐genotypic regimens with SOF/VEL with or without VOX not only have excellent efficacy and safety, but also significantly positively impact patients’ experience both during treatment and after achieving sustained virologic response in DAA‐naïve patients with HCV. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - November 27, 2017 Category: Drugs & Pharmacology Authors: Z. M. Younossi, M. Stepanova, I. M. Jacobson, T. Asselah, E. J. Gane, E. Lawitz, G. R. Foster, S. K. Roberts, A. J. Thompson, B. E. Willems, T. M. Welzel, B. Pearlman, I. Younossi, A. Racila, L. Henry Tags: ORIGINAL ARTICLE Source Type: research

Market share and costs of biologic therapies for inflammatory bowel disease in the USA
ConclusionThe vast majority of costs allocated to out‐patient IBD medications in the USA is attributed to increasing use of biologic therapies despite the relative minority of biologic‐taking patients. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - November 22, 2017 Category: Drugs & Pharmacology Authors: H. Yu, D. MacIsaac, J. J. Wong, Z. M. Sellers, A. A. Wren, R. Bensen, C. Kin, K. T. Park Tags: ORIGINAL ARTICLE Source Type: research

Long ‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis
Summary BackgroundAdalimumab is used to treat moderate to severe Crohn's disease (CD) and ulcerative colitis (UC) when conventional therapies fail. AimTo update long‐term adalimumab safety from CD and UC trials; the previous report was CD only, 3160 patients/3402 patient‐years (PYs). MethodsTreatment‐emergent adverse events (AEs; first dose to 70 days after last dose/December 31, 2015) in adults in phase 2/3 and 3/3b trials and open‐label extensions were coded using Medical Dictionary for Regulatory Activities (MedDRA‐v18.1). Rates were assessed as events/100 (E/100 PYs). ResultsThe database (16 trials; CD, ...
Source: Alimentary Pharmacology and Therapeutics - November 21, 2017 Category: Drugs & Pharmacology Authors: J. ‐F. Colombel, W. J. Sandborn, W. Reinisch, L. Peyrin‐Biroulet, R. Panaccione, P. Rutgeerts, S. B. Hanauer, S. Ghosh, G. Van Assche, A. M. Robinson, W. Lau, J.‐F. Maa, B. Huang, B. Pappalardo, H. Read Tags: ORIGINAL ARTICLE Source Type: research

Exposure ‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
Summary BackgroundTherapeutic drug monitoring may optimize therapy for Crohn's disease (CD). AimTo use a population pharmacokinetic model that accounts for the time‐varying nature of covariates to simulate certolizumab pegol (CZP) concentrations to evaluate the exposure‐response relationship for CZP in Crohn's disease. MethodsAdults (N = 2157) with Crohn's disease were treated with CZP in nine clinical trials. Simulated CZP concentrations were compared to outcomes at weeks 6 and 26, including Crohn's disease activity index (CDAI) response (decrease from baseline ≥ 100 points), remission (CDAI&nbs...
Source: Alimentary Pharmacology and Therapeutics - November 21, 2017 Category: Drugs & Pharmacology Authors: N. Vande Casteele, B. G. Feagan, S. Vermeire, M. Yassine, J. Coarse, G. Kosutic, W. J. Sandborn Tags: ORIGINAL ARTICLE Source Type: research

Genetic risk factors for perception of symptoms in GERD: an observational cohort study
ConclusionsGenetic variation within GNβ3 predicts oesophageal symptom burden and affect, but not oesophageal acid burden or symptom association with reflux episodes. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - November 17, 2017 Category: Drugs & Pharmacology Authors: A. Patel, S. Hasak, B. D. Nix, G. S. Sayuk, R. D. Newberry, C. P. Gyawali Tags: ORIGINAL ARTICLE Source Type: research

Early drug and anti ‐infliximab antibody levels for prediction of primary nonresponse to infliximab therapy
Summary BackgroundPrimary nonresponse, defined as lack of clinical benefit during the induction phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms underlying primary nonresponse have not yet been clearly defined. AimTo evaluate the association of early (week 2 and week 6) induction infliximab and anti‐infliximab antibody levels with primary nonresponse. MethodsA retrospective observational case‐control study of inflammatory bowel disease patients treated with infliximab and followed at Sheba Medical Center between 2009 and 2016 was performed. Pre‐infusion infliximab and antibodies to i...
Source: Alimentary Pharmacology and Therapeutics - November 10, 2017 Category: Drugs & Pharmacology Authors: H. Bar ‐Yoseph, N. Levhar, L. Selinger, U. Manor, M. Yavzori, O. Picard, E. Fudim, U. Kopylov, R. Eliakim, S. Ben‐Horin, Y. Chowers, B. Ungar Tags: ORIGINAL ARTICLE Source Type: research

Risk factors for biopsy ‐proven advanced non‐alcoholic fatty liver disease in the Veterans Health Administration
Summary BackgroundWith its increasing incidence, nonalcoholic fatty liver disease (NAFLD) is of particular concern in the Veterans Health Administration (VHA). AimsTo evaluate risk factors for advanced fibrosis in biopsy‐proven NAFLD in the VHA, to identify patients at risk for adverse outcomes. MethodsIn randomly selected cases from VHA databases (2005‐2015), we performed a retrospective case‐control study in adults with biopsy‐defined NAFLD or normal liver. ResultsOf 2091 patients reviewed, 399 met inclusion criteria. Normal controls (n = 65) had normal liver function. The four NAFLD cohorts included: N...
Source: Alimentary Pharmacology and Therapeutics - November 8, 2017 Category: Drugs & Pharmacology Authors: Y. A. Patel, E. J. Gifford, L. M. Glass, R. McNeil, M. J. Turner, B. Han, D. Provenzale, S. S. Choi, C. A. Moylan, C. M. Hunt Tags: ORIGINAL ARTICLE Source Type: research

Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES
ConclusionsIn patients with chronic HCV infection, increasing proton pump inhibitor use is associated with a dose‐dependent risk of progression of chronic liver disease to cirrhosis, as well as an increased risk of hepatic decompensation and hepatocellular carcinoma. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - November 3, 2017 Category: Drugs & Pharmacology Authors: D. K. Li, P. Yan, A ‐B. Abou‐Samra, R. T. Chung, A. A. Butt Tags: ORIGINAL ARTICLE Source Type: research

Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension
ConclusionTaurine is safe and may reduce portal pressure in cirrhotic patients. More studies on the underlying mechanisms of action and long‐term effects of taurine supplementation are warranted. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - November 3, 2017 Category: Drugs & Pharmacology Authors: R. Schwarzer, D. Kivaranovic, M. Mandorfer, R. Paternostro, D. Wolrab, B. Heinisch, T. Reiberger, M. Ferlitsch, C. Gerner, M. Trauner, M. Peck ‐Radosavljevic, A. Ferlitsch Tags: ORIGINAL ARTICLE Source Type: research

Letter: safety and efficacy of using statins in patients with cirrhosis —authors' reply
This article is linked to Zhao et al and Bang et al papers. To view these articles visit https://doi.org/10.1111/apt.14357 and https://doi.org/10.1111/apt.14243. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - November 3, 2017 Category: Drugs & Pharmacology Authors: U. C. Bang, T. Benfield, F. Bendtsen Tags: LETTER TO THE EDITORS Source Type: research

Letter: safety and efficacy of using statins in patients with cirrhosis
This article is linked to Bang et al papers. To view these articles visit https://doi.org/10.1111/apt.14243 and https://doi.org/10.1111/apt.14364. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - November 3, 2017 Category: Drugs & Pharmacology Authors: J. Zhao, H. Tian, C. Liang Tags: LETTER TO THE EDITORS Source Type: research

Letter: statins and cirrhosis
This article is linked to Bang et al paper. To view this article visit https://doi.org/10.1111/apt.14243. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - November 3, 2017 Category: Drugs & Pharmacology Authors: V. G. Athyros, N. Katsiki, D. P. Mikhailidis Tags: LETTER TO THE EDITORS Source Type: research

Letter: rifaximin is more than helping hepatic encephalopathy —it also saves lives
This article is linked to Kang et al paper. To view this article visit https://doi.org/10.1111/apt.14275. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - November 3, 2017 Category: Drugs & Pharmacology Authors: Y. ‐L. Wang, H.‐J. He, X.‐X. Xiao, Y. Lin, B.‐Q. Wang, S.‐L. Zhu, G.‐S. Yang, S.‐S. Huang, Q.‐G. Yang Tags: LETTER TO THE EDITORS Source Type: research

Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease —Authors' reply
This article is linked to Swaminath et al and Logan et al papers. To view these articles visit https://doi.org/10.1111/apt.14253 and https://doi.org/10.1111/apt.14351. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - November 3, 2017 Category: Drugs & Pharmacology Authors: A. Feathers, A. Swaminath, A. N. Ananthakrishnan, L. Falzon, S. Li Ferry Tags: LETTER TO THE EDITORS Source Type: research

Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease
This article is linked to Swaminath et al and Feathers et al papers. To view these articles visit https://doi.org/10.1111/apt.14253 and https://doi.org/10.1111/apt.14360. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - November 3, 2017 Category: Drugs & Pharmacology Authors: M. Logan, U. Z. Ijaz, R. Hansen, K. Gerasimidis, R. K. Russell Tags: LETTER TO THE EDITORS Source Type: research